PTPRC and neoplasm: Other markers evaluated in a range of tumors included CD3 (pan-lymphocyte marker), CD4 (helper T-lymphocyte marker), CD45 (marker for memory T- lymphocytes) and FOXP3 (a nuclear marker to delineate regulatory T-lymphocytes).[11–13] Additionally, cytokines previously suggested as prognostic include tumor IL-12RB2 and tumor IL-7R.[14] CD8 expression has generally been correlated with improved prognosis in solid malignancies, CD4 expression has largely been correlated with CD8 expression, and FOXP3 expression has been associated with no difference in outcomes or poorer prognosis.